Downloads: 1 | Views: 93 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1
Research Paper | Ophthalmology | India | Volume 11 Issue 12, December 2022
Effect of Subconjunctival Bevacizumab Injection on Pterygium
Dr. Sadiya Aijaz [3] | Dr. Sehrish Deva [3] | Dr. Younis Ahmad Dar [3] | Dr. Sidra Javaid [3]
Abstract: This study determined the clinical effect of subconjunctival administration of bevacizumab in patients with primary and recurrent pterygium. Methods: A prospective interventional study involving single-dosing of subconjunctival bevacizumab (0.2 cc). The study consisted of 21 patients with primary and recurrent pterygium. Grading ofpterygium vascularity and thickness was done. The size of the pterygium (measured by surface area in cm?) was recorded from baseline to 12 weeks after injection. Treatment-related complications and adverse events were reported. The main outcome of measurements was the change in size, vascularity, thickness and color intensity. Results: There were 14 males (66.66%) and 7 females (33.33%) of 21 patients with a mean age of 45.5 years (SD 11.68 years).There was a significant difference in the mean surface area of pterygium at different intervals (P < 0.05) and the size of pterygium was reduced. On comparison of the mean pterygium size, there was no significant difference between men and women (P >0.05). There was a significant reduction in the mean pterygium size of patients younger than 45 years in comparison to those older than 45 years after three month (P =0.037), but after 6 months, this difference was not significant (P = 0.338). The reduction of color intensity in both eyes was significant (P =0.031). Subconjuctival bevacizumab injection is useful in management of patients with primary and recurrent pterygium without significant local or systemic adverse effects.
Keywords: subconjunctival bevacizumab, primary and recurrent pterygium, change in size, vascularity, thickness and color intensity of pterygium
Edition: Volume 11 Issue 12, December 2022,
Pages: 685 - 687